ArticleDiabetes, obesity & metabolism2026
Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsUrogenital adverse events are common with sodium-glucose co-transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (GTI) and phimosis among adults with Type 2 diabetes who initiated empagliflozin versus dapagliflozin. MATERIALS AND
methodsThis population-based, active-comparator, new-user cohort study emulating a target trial included adult metformin users initiating empagliflozin or dapagliflozin during 2015-2022. We identified UTIs and GTIs through pharmacy antimicrobial prescriptions and inpatient or outpatient diagnoses. Phimosis was identified through hospital diagnoses and procedure codes. Baseline characteristics were balanced using inverse probability of treatment weighting, and cumulative risks and risk ratios were estimated using an intention-to-treat approach.
resultsThe study population included 53 083 empagliflozin and 33 349 dapagliflozin initiators, with median follow-up ranging from 2.6 to 3.8 years across outcomes. The weighted 1-year UTI risk was similar between groups (empagliflozin 10.3% vs. dapagliflozin 10.6%, RR 0.98 [95% CI, 0.95-1.01]). Risks of GTI (2.2% vs. 2.0%, RR 1.14 [95% CI, 1.04-1.25]), and phimosis (1.0% vs. 0.8%, RR 1.23 [95% CI, 1.04-1.52]) were slightly higher with empagliflozin, though absolute risk differences were small. Safety profiles were consistent throughout 5-year follow-up.
conclusionsInitiation of empagliflozin versus dapagliflozin was associated with comparable absolute risks of urogenital adverse events, and slightly higher relative risks of GTI and phimosis among empagliflozin initiators, supporting broadly similar safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.